InnoCare's Orelabrutinib Covered by More City Commercial Insurance


Beijing, May 12, 2021—— InnoCare’s BTK inhibitor orelabrutinib has been recently included in the Chengdu and Shanghai city commercial insurance, which will further enhance the accessibility of orelabrutinib and benefit more lymphoma patients. InnoCare has been actively exploring diversified and innovative payment methods.

Before Chengdu and Shanghai, orelabrutinib has been included in more city commercial insurance including Zhoushan and Quzhou of Zhejiang Province, Linyi of Shandong Province, and Zhuhai, Foshan and Huizhou of Guangdong province, Suzhou of Jiangsu Province and Kunming of Yunnan Province. By now, orelabrutinib has been covered by 16 city or provincial commercial insurance.

On December 25, 2020, orelabrutinib was approved by China National Medical Products Administration (NMPA) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.